Skip to main content

Table 4 Top 20 significantly enriched KEGG pathways of differentially expressed proteins identified by discovery proteomics

From: Proteomic analysis in lupus mice identifies Coronin-1A as a potential biomarker for lupus nephritis

KEGG pathway KEGG ID Hits p value FDR
12 weeks
 Metabolic pathways mmu01100 483 1.45E−62 1.92E−61
 Biosynthesis of antibiotics mmu01130 144 4.13E−52 5.47E−51
 Carbon metabolism mmu01200 85 6.32E−35 8.38E−34
 Oxidative phosphorylation mmu00190 94 4.13E−34 5.48E−33
 Parkinson’s disease mmu05012 91 4.78E−28 6.35E−27
 Alzheimer’s disease mmu05010 94 8.33E−23 1.11E−21
 Ribosome mmu03010 82 2.94E−22 3.90E−21
 Huntington’s disease mmu05016 97 2.92E−20 3.88E−19
 Valine, leucine and isoleucine degradation mmu00280 43 1.66E−19 2.20E−18
 Glycolysis/gluconeogenesis mmu00010 47 1.46E−18 1.93E−17
 Pyruvate metabolism mmu00620 33 8.28E−17 1.44E−15
 Non-alcoholic fatty liver disease (NAFLD) mmu04932 75 5.96E−15 7.95E−14
 Propanoate metabolism mmu00640 25 1.82E−14 2.42E−13
 Biosynthesis of amino acids mmu01230 46 3.93E−14 5.21E−13
 Fatty acid degradation mmu00071 35 6.34E−14 8.41E−13
 Peroxisome mmu04146 48 1.10E−13 1.46E−12
 Citrate cycle (TCA cycle) mmu00020 27 1.15E−13 1.53E−12
 Proteasome mmu03050 33 1.18E−13 1.56E−12
 Glutathione metabolism mmu00480 36 1.39E−12 1.84E−11
 Glycine, serine and threonine metabolism mmu00260 28 6.95E−11 9.22E−10
24 weeks
 Metabolic pathways mmu01100 490 1.27E−57 1.69E−56
 Biosynthesis of antibiotics mmu01130 144 4.10E−49 5.45E−48
 Carbon metabolism mmu01200 87 3.25E−35 4.32E−34
 Oxidative phosphorylation mmu00190 97 5.63E−35 7.49E−34
 Parkinson’s disease mmu05012 96 2.40E−30 3.19E−29
 Alzheimer’s disease mmu05010 98 9.13E−24 1.21E−22
 Huntington’s disease mmu05016 102 1.41E−21 1.88E−20
 Ribosome mmu03010 82 9.71E−21 1.29E−19
 Glycolysis/gluconeogenesis mmu00010 50 1.35E−20 1.79E−19
 Valine, leucine and isoleucine degradation mmu00280 43 1.30E−18 1.72E−17
 Pyruvate metabolism mmu00620 34 2.25E−17 2.99E−16
 Propanoate metabolism mmu00640 26 1.88E−15 2.51E−14
 Fatty acid degradation mmu00071 37 3.48E−15 4.57E−14
 Biosynthesis of amino acids mmu01230 47 4.93E−14 6.55E−13
 Citrate cycle (TCA cycle) mmu00020 27 4.22E−13 5.60E−12
 Proteasome mmu03050 33 5.43E−13 7.22E−12
 Non-alcoholic fatty liver disease (NAFLD) mmu04932 73 1.26E−12 1.67E−11
 Peroxisome mmu04146 47 4.19E−12 5.57E−11
 Glutathione metabolism mmu00480 36 6.85E−12 9.10E−11
 Fatty acid metabolism mmu01212 32 5.96E−10 7.93E−09
36 weeks
 Metabolic pathways mmu01100 539 3.89E−63 5.17E−62
 Biosynthesis of antibiotics mmu01130 152 3.49E−50 4.64E−49
 Carbon metabolism mmu01200 94 6.45E−39 8.58E−38
 Oxidative phosphorylation mmu00190 100 1.22E−33 1.62E−32
 Parkinson’s disease mmu05012 95 1.04E−25 1.38E−24
 Ribosome mmu03010 90 3.47E−23 4.61E−22
 Alzheimer’s disease mmu05010 101 4.65E−22 6.18E−21
 Glycolysis/gluconeogenesis mmu00010 49 1.58E−17 2.10E−16
 Huntington’s disease mmu05016 101 1.91E−17 2.54E−16
 Valine, leucine and isoleucine degradation mmu00280 43 8.57E−17 1.44E−15
 Biosynthesis of amino acids mmu01230 52 4.61E−16 5.88E−15
 Pyruvate metabolism mmu00620 34 6.83E−16 8.88E−15
 Proteasome mmu03050 36 1.35E−14 1.80E−13
 Non-alcoholic fatty liver disease (NAFLD) mmu04932 81 2.34E−14 3.11E−13
 Propanoate metabolism mmu00640 25 7.73E−13 1.03E−11
 Fatty acid degradation mmu00071 36 1.04E−12 1.39E−11
 Glutathione metabolism mmu00480 38 4.26E−12 5.66E−11
 Citrate cycle (TCA cycle) mmu00020 27 5.98E−12 7.95E−11
 Peroxisome mmu04146 49 1.09E−11 1.45E−10
 Fatty acid metabolism mmu01212 34 3.02E−10 4.01E−09
  1. All 20 pathways are common at all three time points. The total list of significantly dysregulated pathways is found in supplementary tables, S3.1, S3.2 and S3.3. Analysis was performed using Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources